Erythromycin Base

Producers shown on SFDA

(Record date:26/08/2021）

Producers shown on EP
(Quoted from EP website；record date:26/08/2021）

Producer:Shandong New Time Pharmaceutical Co., Ltd. is a member enterprise of Lunan Pharmaceutical Group. It is a national key high-tech enterprise. It was founded on March 23, 2002. It has more than 4000 employees. The overall planning covers an area of 8600 Mu and the planned investment is 10 billion yuan. It is mainly engaged in the R & D and production of traditional Chinese medicine, western medicine, chemical raw materials, preparations, antibiotics, biopharmaceutical and genetic engineering.

The enterprise has established a quality assurance system in line with international quality supervision concepts such as ICH, FDA and EDQM. All dosage forms and varieties have passed the new national GMP certification and won the title of "the best industrial enterprise in China's pharmaceutical R & D product line" for many times. The overall quality management level ranks in the forefront of the same industry in the country.

Staff size:4000-4990 persons

Registered capital:RMB 363.908 million

Producer:HEC Pharmaceutical Co., Ltd. formerly known as HEC Biochemical Pharmaceutical Co., Ltd., was established on January 12, 2004. It is a large-scale western medicine manufacturing and bioengineering enterprise mainly engaged in the R & D, production and sales of macrolide antibiotics, antiviral drugs, insulin and other drugs. At present, the company is the largest in the world It is a manufacturer of macrolide antibiotic API with the most advanced technology. Its main customers are pharmaceutical giants such as Abbott and Pfizer. It is also one of the earliest enterprises engaged in the R & D, registration and production of overseas generic drugs.

The company attaches great importance to the research and development of preparation technology, and has established a variety of preparation technology platforms such as slow and controlled release and transdermal technology. The company is also carrying out the layout of preparation products in Europe and America. At present, seven products have passed the EU cGMP certification, three products have passed the FDA certification, and macrolide APIs have passed the FDA cGMP certification.

Staff size:2000-2999 persons

Registered capital:RMB 813.368 million

Producer:In February 2021, Guangdong Shaoguan Jiqi Pharmaceutical Co., Ltd. was restructured and reorganized by the Listed Company Guilin Jiqi Pharmaceutical Co., Ltd. on the basis of the former Guangdong Shaoguan pharmaceutical factory. It is one of the key national manufacturers of antibiotic drugs. It is located at the foot of Furong mountain, Shaoguan City, Guangdong Province, covering an area of 120000 square meters. It was founded in 1965.

Staff size: About 50 persons 

Registered capital:RMB 71 million

Producer:Taishan Chemical Pharmaceutical Co., Ltd. is a provincial high-tech enterprise, a famous trademark enterprise in Guangdong Province and a national GMP certified enterprise. It is located in Taishan City, Guangdong Province, a beautiful hometown of overseas Chinese and tourist resort.

Production scope: API and pharmaceutical intermediates, tablets, capsules (including cephalosporins), oral solution. With more than 20 years of experience in the production of erythromycin and its derivatives, the leading products are erythromycin, erythromycin relying, erythromycin Ethylsuccinate, erythromycin stearate, etc. The products are of excellent quality, controllable quality and well-known in the Chinese and foreign markets. In recent years, we have also systematically developed and focused on the production of immunosuppressant products, including cyclosporine, tacrolimus and its preparations.

The company has an efficient quality assurance system and organizes production in strict accordance with GMP; Perfect after-sales service. The plant facilities and production equipment are excellent, the testing instruments are advanced, and the sewage treatment meets the discharge standard. The product quality meets the Pharmacopoeia standards of China, the United States, Europe and the United Kingdom.

Staff size:About 50 persons

Registered capital:RMB 27 million

Producer:Henan Xinxiang Huaxing Pharmaceutical Factory is located in the Central Plains. It is close to Beijing Guangzhou railway in the West and national highway 107 in the East. The transportation is very convenient. The factory covers an area of more than 300000 square meters, with a construction area of more than 130000 square meters, and has a group of high and intermediate technical teams and management personnel. The annual production of inosine is more than 200 tons, penicillin is more than 1000 tons, 6-APA, ampicillin, ampicillin sodium, erythromycin and penicillin powder injection are 600 million, and commodity hall powder is 20000 tons. The production of dipyridamole, ofloxacin, jiemycin, n-butanol, acetone, ethanol, butyl acetate, ethyl acetate and other products. Huaxing Pharmaceutical Factory has established a perfect quality control and quality assurance system, and has advanced testing instruments at home and abroad. Its products are sold at home and abroad and are praised by our customers. Huaxing Pharmaceutical Factory is one of China's large inosine and antibiotic manufacturers. Party and state leaders Jiang Zemin and Li Peng visited and spoke highly of it.

Staff size:100-199 persons

Registered capital: RMB 799 million

Producer:Shanghai Xiandai Hasen(Shangqiu) Pharmaceutical Co., Ltd. is a holding company invested and established by the listed company Shanghai Hyundai Pharmaceutical Co., Ltd. (stock code 600420). The major shareholder is China Pharmaceutical Group Corporation. It is a pharmaceutical enterprise built in strict accordance with the modern enterprise system and the requirements of national GMP. It is a diversified enterprise integrating drug R & D, production and sales Modern national essential drug production base. The company covers an area of more than 500 mu, has a registered capital of 83.29 million yuan, a total asset of more than 600 million yuan, and has more than 1600 employees, including more than 800 professional and technical personnel; The company has obtained 163 drug production approval products, and has GMP production lines for small volume injections, oral solid preparations (tablets, capsules, granules), APIs and other dosage forms. The annual production capacity of small volume injections is 4 billion tubes, 6 billion tablets (granules and bags) of oral solid preparations and 1200 tons of API.

Staff size:1000-1999 persons

Registered capital:RMB 83.29 million

Producer:Zhejiang Nexchem Pharmaceutical Co., Ltd.was established in December 2002, with advanced manufacturing equipment and technology. The production plant is located in Linjiang Industrial Zone, Wucheng District, Jinhua City, Zhejiang Province, covering an area of 338 mu (252012 square meters). The registered capital of the company is 370 million yuan. It is a modern manufacturing enterprise mainly engaged in R & D, production and sales of APIs.

The company has obtained GMP certificates of azithromycin, clarithromycin, roxithromycin, benzhydrazine hydrochloride and fenofibrate respectively, and COS certificates of clarithromycin, fenofibrate and glimepiride. At the same time, clarithromycin was certified by PMDA of Japan.

Staff size:About 300 persons

Registered capital:RMB 374.438094 million 

Producer:Zhejiang Asia Pacific Pharmaceutical Co., Ltd., formerly known as Zhejiang Asia Pacific pharmaceutical factory, was founded in 1989 and is located at No. 1152, Yunji Road, Shaoxing County, Zhejiang Province. The shareholding system reform was completed in 2001 and was officially listed on Shenzhen Stock Exchange on March 16, 2010. The company's factory covers a total area of more than 120000 square meters, has a registered capital of 204 million yuan, has a total asset of 820 million yuan, and has more than 900 employees, including more than 300 with college degree or above.

The company is a professional and large-scale national high-tech enterprise integrating scientific research, production and sales and a key high-tech enterprise of the national torch plan. The company has tablets (including penicillins), hard capsules (including cephalosporins and penicillins), transdermal patches (hormones), freeze-dried powder injections, powder injections (cephalosporins), azithromycin Roxithromycin and other 11 modern pharmaceutical production workshops that have passed the national GMP quality system certification, with a total of 97 drug approval numbers.  

Staff size:About 900 persons

Registered capital:RMB 536 million 600 thousand

Producer:Heze Fangming Pharmaceutical Co., Ltd. is subordinate to Shandong Fangming Pharmaceutical Group Co., Ltd. the company mainly produces the second-generation macrolide antibiotics with advanced technology and excellent quality.

Staff size:About 100 persons

Registered capital:RMB 10 million

Producer:Shaoxing Xingya Pharmaceutical Co., Ltd., established on August 29, 2017, is a wholly-owned subsidiary of Zhejiang Yatai Pharmaceutical Co., Ltd. Zhejiang Asia Pacific Pharmaceutical Co., Ltd. is a professional and large-scale national high-tech enterprise integrating scientific research, production and sales and a key high-tech enterprise of the national torch plan.

Staff size:50-99 persons

Registered capital:RMB 60 million

Staff size:1000-1999 persons

Registered capital:RMB 138.8 million

Producer:Hunan Jiudian Pharmaceutical Co., Ltd. is a listed pharmaceutical enterprise integrating drug R & D, production and sales. It was incorporated in 2001 and listed on the gem in 2017.

The company has completed the all-round layout of pharmaceutical preparations, traditional Chinese medicine, APIs, pharmaceutical accessories, pharmaceutical commerce and other industries, established a perfect R & D, marketing and production system, and continuously improved the level of operation and management; R & D resources and market resources are increasingly abundant. It has modern production lines including raw material medicine, oral solid preparation, oral liquid preparation, gel paste, pharmaceutical excipient and so on. Preparations and traditional Chinese medicine are produced in Liuyang Economic Development Zone, APIs and excipients are produced in Wangcheng Economic Development Zone, and R & D and commercial sales are in Changsha high tech Zone.

The company is a R & D driven enterprise with sound R & D system and advanced instruments and equipment. It has more than 10000 square meters of research and development sites, forming a complete test platform from small-scale research to pilot test to industrialization. A 400 person R & D team with doctors, masters and returned overseas talents as the main body has been established, with the strongest R & D level in the province. The company's leading products are self-developed. There are nearly 100 products under research and declared products, which will greatly enrich the company's product pipeline. After the new drugs under research are listed, they will become a heavy variety of existing advantageous products.

Staff size:About 1500 persons

Registered capital:RMB 234 million 700 thousand

Producer:Wusuli Ricer Pharmacy Co., Ltd. is a cross regional pharmaceutical enterprise group integrating R & D, production and sales. The group headquarters and marketing center are located in Harbin bungalow economic development zone. The company now has three drug production bases: Hulin, Harbin and Yingchun. The enterprise covers a total area of 900000 square meters and a construction area of 98000 square meters. The total assets of the enterprise are 538 million yuan. The company has a production base of traditional Chinese medicine extraction and large and small volume injections based on Hulin headquarters; There are solid preparations and food, drug and health products production bases dominated by Harbin branch; There are chemical raw materials and penicillin production bases dominated by Yingchun branch; And the research institute focusing on Dejing biotechnology, focusing on the company's advantages, national policies and government guidance for the R & D and technical application of drugs, food and health products.

Staff size:/

Registered capital:/

Producer:Huangshi Shixing Pharmaceutical Co., Ltd., established on June 16, 2004, is a private enterprise and other limited liability companies.

The company has focused on the R & D and production of chemical APIs for nearly 30 years, has production and inspection plants, equipment, instruments and supporting facilities in line with China's GMP standards, and has a perfect platform for API R & D and pilot test. Through independent research and development and industry university research cooperation, it has obtained a number of product core technologies, and the quality of its main products has reached the standards of the United States Pharmacopoeia (USP) and the European Pharmacopoeia (EP).

The company is a national "high-tech enterprise", "AAA credit enterprise", a "science and technology small giant enterprise" in the subdivided field of pillar industries in Hubei Province, and a specialized and new "small giant" enterprise in Hubei Province. The company's technology center was recognized as the "provincial enterprise technology center" in 2019, with an average annual R & D cost of more than 10 million yuan. Now it has many invention patents and more than 130 R & D personnel. It has passed the three management system certification of ISO9001 quality, ISO14001 environment and iso45001 occupational health and safety, has the right of self import and export, and has obtained the registration certificate of customs declaration unit issued by China Customs.

Staff size:300-399 persons

Registered capital:RMB 250 million

Producer:Xi'an Lijun Pharmaceutical Co., Ltd. is a state-owned pharmaceutical enterprise reorganized and established on the basis of the former Xi'an Lijun Pharmaceutical Co., Ltd. Its predecessor, Xi'an pharmaceutical factory, was founded in Yan'an, the holy land of revolution, in 1938. It has a pharmaceutical history of 70 years. Two generations of leaders have written inscriptions for the enterprise. There are more than 1000 professional and technical talents, mainly engaged in new preparations, pharmaceutical raw materials, characteristic OTC and high-quality health products.  

The company has an annual output of 7 billion tablets, 50 million capsules, 100 million packages of granules, 100 million water injections, 30 million powder injections and 20 million freeze-dried powder injections. The internationally advanced and domestic first-class modern oral liquid and modern soft capsule production line introduced from the United States, Japan, Germany and Italy can produce 20-30 million bottles of oral liquid and 200 million soft capsules per year. The raw materials tetracycline hydrochloride, erythromycin and phosphoerythromycin have passed the FDA certification. Tetracycline hydrochloride has been exported to the United States for 22 consecutive years and has passed the European cos certification.

Erythromycin is the first in China to pass FDA certification; Phosphoerythromycin is the first developed and produced in China. The company ranks first in the production and sales of erythromycin, erythromycin Ethylsuccinate preparations, raw materials and azithromycin lyophilized powder needles in China. It is the largest production base of macrolide antibiotics in China.。

Staff size:1000-1999 persons

Registered capital:RMB 620 million

Producer:DZD (Heze) Pharmaceutical Co.,Ltd. is a growing company dedicated to the research and production of high-quality active pharmaceutical ingredients, intermediates and finished dosage forms on a cost-effective basis. 

 Starting with anthracyclines, we have expanded our production lines into a series of oncology drugs for different applications, making us a promising player in anti-cancer generic drugs.  Other than oncology field, we are also developing into immunosuppressants, specialized antibiotics as well as veterinary API. 

 With a total plant area of 25,700 m2, we have capabilities in fermentation, DSP and chemical synthesis.  All plants were designed and installed under cGMP standards.  Our start-of-the-art QC equipment together with strict QA management procedures makes sure that our clients are provided with consistent qualities.

Staff size:100-199 persons

Registered capital:RMB 89.91 million

Producer:Ningxia Qiyuan Pharmaceutical Co., Ltd., established in January 2001, was restructured and merged by the former state-owned enterprise Ningxia pharmaceutical factory and Ningxia traditional Chinese medicine factory. After nearly 20 years of unremitting efforts, the company has developed into a modern large-scale comprehensive biopharmaceutical enterprise well-known at home and abroad. Relying on the regional advantages suitable for the development of biopharmaceutical in Ningxia, the company vigorously develops the R & D and production of antibiotic API, vitamin API and corn deep processing. The company's tetracycline API series products are the exclusive varieties in the world. Erythromycin API and its synthetic products are currently one of the three major suppliers in the world. Vitamin C series products occupy a place in the domestic and foreign markets with their scale and quality.

The company is listed as a national high-tech enterprise, and the company's technology center is a national enterprise technology center. Erythromycin and tetracycline hydrochloride APIs have passed FDA, cos and eugmp certification in Europe, as well as official quality audits in India, Japan and other countries. Vitamin C products of the company have passed international food certification, such as halal, kosher, etc. The company's products are sold to Europe, South America, Africa, Southeast Asia and other dozens of countries and regions.

Staff size:1000-1999 persons

Registered capital:RMB 2.91 million

Producer:Zhejiang Zhenyuan Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of the Shenzhen listed company "Zhejiang Zhenyuan" and a national key high-tech enterprise. The company has a registered capital of 300 million yuan, covers an area of 345 mu, has more than 900 employees, and about half of them are junior college or above. With a construction area of 120000 square meters, the company has built seven API workshops and two preparation workshops, and has a comprehensive production capacity of API production by chemical synthesis and biological fermentation, oral solid preparations and small volume injections.

Staff size:About 900 persons

Registered capital:RMB 300 million

Producer:Shanghai Yurui Biotechnology (Anyang) Pharmaceutical Co., Ltd., with an investment of 120 million yuan, was built in 2005. It is a modern pharmaceutical enterprise in Anyang County. The company is located in Hanling Industrial Park, Anyang, Henan, covering an area of 62911m2 and a construction area of 20000 m2.

There are two production workshops: API workshop and oral solid preparation workshop. The API workshop has three advanced production lines with an annual production capacity of 1000 tons. The oral solid preparation workshop mainly produces tablets, granules and capsules, and has six production lines with an annual output of 15 billion tablets (granules and bags).  

The company has a sound organizational structure, including quality supervision department, production technology department, procurement department, sales department, finance department, general manager's office and central laboratory. It has 165 employees and provincial enterprise technology center. The company has 106 approval numbers for tablets, capsules, granules and APIs.

Staff size:100-199 persons

Registered capital:RMB 81.66 million

Producer:Foshan Nanhai Beisha Pharmaceutical Co., Ltd. is located in Beisha Industrial Zone, Lishui Town, Nanhai District, Foshan City. It is a large manufacturer of pharmaceutical raw materials in South China and has passed GMP certification. Produce a variety of pharmaceutical raw materials, mainly anti infection and anti-inflammatory raw materials - sulfonamides and macrolides, such as sulfamethazine and its sodium salt, sulfadiazine and its sodium salt, sulfamethoxazole and trimethoprim; Roxithromycin et al. The products have been exported to Europe, America, Japan, Southeast Asia and other international markets, with an annual output of more than 3000 tons.

Since the establishment of our factory in 1992, our company has been trying to standardize production management and improve quality assurance system to improve product quality. Over the years, our products have been produced in strict accordance with the process procedures, and the product quality standards have been in strict accordance with the standards of Chinese Pharmacopoeia, American Pharmacopoeia, Japanese Pharmacopoeia, British Pharmacopoeia or European Pharmacopoeia. After years of efforts, our products have won a good reputation in the international market.

Staff size:200-299 persons

Registered capital:RMB 48 million

Producer:Zhejiang Jinhua CONBA Bio-pharm. Co., Ltd. (JINHUA CONBA) is a major subsidiary company of CONBA group, which headquarters in Hangzhou. CONBA group have more than twenty subsidiary companies.

Founded in 1958, Jinhua CONBA is located in Jinhua Pharmaceutical Industry zone, covering 85400 square meters, which takes three and a half hours to Shanghai and two hours to Hangzhou by car. It possesses total assets of RMB 500 million and the turn over in 2011 is RMB 560 million. It has more than 1000 employees, over 40% of which are technicians.

JINHUA CONBA produces both finished products and APIs including Lyophilized Powder for Injection, Capsules, Tablets and Antibiotics, Semi-sythetic antibiotics and Chemical synthetic bulk drugs. JINHUA CONBA is continually improving its quality management system and approved by European cGMP, U.S.A FDA , ISO9001, ISO14001 and Chinese GMP. It has a sales network which covers 50 major cities in China and our products are widely exported to Europe,South America and Asia.

Staff size:900-999 persons

Registered capital:RMB 520 million

Producer:Chongqing Daxin Pharmaceutical Co., Ltd. (herein referred as Chongqing Daxin) was established in 1941. It is a core member of PKU HealthCare Industry，which has been praised as the Key High-tech Enterprise of the National Torch Program, Nationwide Key Enterprise in Chemical and Pharmaceutical Industry, one of the National Top 100 Pharmaceutical Enterprises and the Exportation brand leader enterprise supported by Chongqing government. After over 70 year's development, it has become a biotech oriented and comprehensive pharmaceutical company which covers areas of APIs and finished dosages.

Daxin pharmaceutical has a perfect quality assurance system. The company has passed GMP certification, FDA certification and European EDQM certification respectively. It can provide customers with high-quality products with different standards such as CP, USP and EP.

Staff size:500-599 persons

Registered capital:RMB163.32 million 

Producer:Hebei Dongfeng Pharmaceutical Co., Ltd. is a famous modern large pharmaceutical enterprise in China. The API produced has passed the national GMP certification and EU cos certification, and is actively applying for FDA certification. Over the years, relying on strict GMP management, stable product quality and perfect marketing services, various products have been selling well in domestic and foreign markets. At the same time, Dongfeng pharmaceutical has also won a good reputation.

The annual production of doxycycline hydrochloride, the fist product of Dongfeng pharmaceutical, reaches 1000 tons, and the export volume occupies a leading position in the world. The company has increased its investment in azithromycin API, carried out a series of technical innovation and management upgrading, improved the quality day by day, and formed large-scale production, with an annual output of 120 tons. In order to make the products enter the international high-end market, the company has specially purchased the leading testing instruments from the United States, which has reached the quality standard of the 29th edition of the United States Pharmacopoeia.

Staff size:50-99 persons

Registered capital:RMB 50 million

Producer:Zhejiang Hisun Pharmaceutical Co., Ltd. was founded in 1956. In 2000, Hisun issued A-shares in Shanghai stock exchange, but it continues to remain a state-owned enterprise. Hisun is one of the largest antibiotics and anti-tumor drug production bases in the country. It has won several titles, including first batch of innovative enterprises, national technology innovation demonstration enterprises, and "National Industrial Brand Demonstration Enterprise” of the Chinese Ministry of Industry and Information Technology. 

Hisun began as a small chemical factory and entered the pharmaceutical field in the early 1970s. Since its founding over 60 years ago in 1956, Hisun has amassed a total asset worth of 21.8 billion RMB. While Hisun is primarily engaged in the R&D, manufacturing, and sales and marking of API and final dosage forms of chemical and biological drugs, its core business has extended to include branded generic drugs, biosimilarst and other innovative drugs. 

Staff size:About 9000 persns

Registered capital:RMB 1 billion 169 million

Producer:Chifeng Aike Pharmaceutical Technology Co., Ltd. (hereinafter referred to as our company), established in March 2000, is a manufacturer of various APIs and chemical intermediates, a ephedrine manufacturer designated by the State Food and drug administration, and a national high-tech enterprise. At present, it is a member enterprise of Shanghai Pharmaceutical Group Co., Ltd.

The company's products are exported at home and abroad, and its export business covers Europe, Asia, America and other places. The domestic business covers all provinces except Tibet, and the domestic market share of the products is nearly 50%. The company has successively passed the quality audit of international famous pharmaceutical enterprises such as Sino US Stryker, Wyeth Baigong pharmaceutical, Shanghai Squibb and Shanghai Johnson & Johnson pharmaceutical, and has become their stable supplier.

Staff size:200-299 persons

Registered capital:RMB 40.9 million

Producer:Hunan Er-kang Pharmaceutical Co., Ltd., established in October 2003, is a leading enterprise of pharmaceutical excipients with the largest scale and the most complete varieties in China; It is also one of the few enterprises in China that have the registration approval documents of new penicillin antibiotics - sulbacillin sodium API and finished products  。 In 2014, the company successfully broke through the technical bottleneck of the industrialization of starch plant capsules, a new high-end excipient variety, and became the world's first enterprise in the industrialization of starch capsules  。 The company was listed on Shenzhen Stock Exchange on September 27, 2011. It is the first listed company in China's pharmaceutical excipients industry.

Staff size:About 1700 persons

Registered capital:RMB 2 billion 63 million

For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978